Creta Massimiliano, Shariat Shahrokh F, Marra Giancarlo, Gontero Paolo, Rossanese Marta, Morra Simone, Teoh Jeremy, Kishan Amar U, Karnes R Jeffrey, Longo Nicola
Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy.
Department of Urology, Medical University of Vienna, Vienna, Austria.
Prostate Cancer Prostatic Dis. 2024 Sep 2. doi: 10.1038/s41391-024-00883-3.
To date, radio-recurrent prostate cancer (PCa) ranks as the fourth most common urological malignancy when considering the number of men with localized PCa who undergo radiation treatment and subsequently experience a biochemical recurrence. This systematic review aimed to summarize available evidence about the outcomes of local salvage strategies in patients with local PCa recurrence following primary external-beam radiation therapy (EBRT).
We conducted a comprehensive bibliographic search on MEDLINE, Scopus, and Web of Science Core Collection databases in October 2023 to identify studies published in the last 20 years evaluating outcomes of local salvage procedures in patients with locally radio-recurrent PCa following EBRT. The meta-analysis was performed using ProMeta 3 software when two or more studies reported the same outcome. The effect size (ES) was estimated using rates reported with its 95% confidence interval (CI).
Overall, 28 studies (6 prospective and 22 retrospective) including 1544 patients were included in the review. Two-year recurrence-free survival (RFS) was 84.0% (95% CI: 67.0-93.0%), 69.0% (95% CI: 42.0-87.0%), 58.0% (95% CI: 43.0-71.0%), and 45% (95% CI: 38.0-52.0%), for patients undergoing brachytherapy (BT), EBRT, Cryotherapy and High-Intensity Focused Ultrasound (HIFU), respectively. After salvage prostatectomy, RFS ranged from 75% to 78.5% at a median follow-up ranging from 18 to 35 months. Estimates for severe gastrointestinal toxicity were 2%, 3%, 3%, 4%, and 11% following cryotherapy, BT, HIFU, EBRT, and salvage radical prostatectomy, respectively.
In patients who underwent EBRT as primary treatment, prostate salvage re-irradiation through BT or EBRT represents the modality providing the best balance between efficacy and safety. Unfortunately, due to the low level of evidence, strong recommendations regarding the choice of any of these techniques cannot be made.
就接受局部前列腺癌放射治疗并随后出现生化复发的男性人数而言,放射性复发性前列腺癌(PCa)是第四常见的泌尿系统恶性肿瘤。本系统评价旨在总结关于原发性外照射放疗(EBRT)后局部PCa复发患者局部挽救策略结果的现有证据。
我们于2023年10月在MEDLINE、Scopus和科学网核心合集数据库中进行了全面的文献检索,以识别过去20年发表的评估EBRT后局部放射性复发性PCa患者局部挽救手术结果的研究。当两项或更多研究报告相同结果时,使用ProMeta 3软件进行荟萃分析。效应大小(ES)使用报告的发生率及其95%置信区间(CI)进行估计。
总体而言,本评价纳入了28项研究(6项前瞻性研究和22项回顾性研究),共1544例患者。接受近距离放疗(BT)、EBRT、冷冻治疗和高强度聚焦超声(HIFU)的患者,其两年无复发生存率(RFS)分别为84.0%(95%CI:67.0 - 93.0%)、69.0%(95%CI:42.0 - 87.0%)、58.0%(95%CI:43.0 - 71.0%)和45%(95%CI:38.0 - 52.0%)。挽救性前列腺切除术后,在18至35个月的中位随访期内,RFS范围为75%至78.5%。冷冻治疗、BT、HIFU、EBRT和挽救性根治性前列腺切除术后严重胃肠道毒性的估计发生率分别为2%、3%、3%、4%和11%。
在接受EBRT作为初始治疗的患者中,通过BT或EBRT进行前列腺挽救性再照射是在疗效和安全性之间提供最佳平衡的方式。不幸的是,由于证据水平较低,无法对这些技术中的任何一种选择给出强有力的推荐。